How And When to Evaluate BSEP Inhibition to Help Reduce Human DILI Risk: ITC Recommendations

Hear Dr. Gerry Kenna, Pharmaceutical Director, Safer Medicines Trust, will discuss pragmatic recommendations by the International Transporter Consortium (ITC) on assessing BSEP inhibition during the drug development process in order to reduce and manage DILI risk.

  • Review conventional and emerging in vitro models
  • Practical advice on conducting BSEP inhibition studies
  • Recommendations for an IND submission strategy

 

Dr Kenna

Dr. Gerry Kenna
Pharmaceutical Director
Safer Medicines Trust

Dr. Gerry Kenna is Pharmaceutical Director of Safer Medicines Trust, a drug safety consultant and Vice President of the Board of Trustees of the Evidence Based Toxicology Collaboration. His work is focused on developing and implementing novel, human biology-based methods that can improve human drug safety evaluation. Previously he was a toxicologist in the pharmaceutical and agrochemical industries for 15 years, having led academic research teams that explored mechanisms underlying serious human adverse drug reactions for 19 years. Dr. Kenna received B.Sc. and Ph.D. degrees in biochemistry from the Universities of Leeds and London, respectively.

Download Now